Clinical Trial Update: Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia [Phase 2, Phase 3]

View source ↗

Summary

A clinical-trial update indicates ongoing phase 2 and phase 3 studies to assess safety and efficacy of EXV-802 and EXV-801 for agitation in Alzheimer's disease …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• EXV-801
• EXV-802

Snippet

Sponsor: Exciva GmbH | Conditions: Agitation Associated With Alzheimer's Disease Dementia | Phase 2, Phase 3 | Status: RECRUITING